Literature DB >> 24850720

The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M Protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy.

Roland Schmitt1, Anne-Lie Ståhl1, Anders I Olin2, Ann-Charlotte Kristoffersson1, Johan Rebetz1, Jan Novak3, Gunnar Lindahl4, Diana Karpman5.   

Abstract

IgA nephropathy (IgAN) is characterized by mesangial cell proliferation and extracellular matrix expansion associated with immune deposits consisting of galactose-deficient polymeric IgA1 and C3. We have previously shown that IgA-binding regions of streptococcal M proteins colocalize with IgA in mesangial immune deposits in patients with IgAN. In the present study, the IgA-binding M4 protein from group A Streptococcus was found to bind to galactose-deficient polymeric IgA1 with higher affinity than to other forms of IgA1, as shown by surface plasmon resonance and solid-phase immunoassay. The M4 protein was demonstrated to bind to mesangial cells not via the IgA-binding region but rather via the C-terminal region, as demonstrated by flow cytometry. IgA1 enhanced binding of M4 to mesangial cells, but not vice versa. Costimulation of human mesangial cells with M4 and galactose-deficient polymeric IgA1 resulted in a significant increase in IL-6 secretion compared with each stimulant alone. Galactose-deficient polymeric IgA1 alone, but not M4, induced C3 secretion from the cells, and costimulation enhanced this effect. Additionally, costimulation enhanced mesangial cell proliferation compared with each stimulant alone. These results indicate that IgA-binding M4 protein binds preferentially to galactose-deficient polymeric IgA1 and that these proteins together induce excessive proinflammatory responses and proliferation of human mesangial cells. Thus, tissue deposition of streptococcal IgA-binding M proteins may contribute to the pathogenesis of IgAN.
Copyright © 2014 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24850720      PMCID: PMC4065838          DOI: 10.4049/jimmunol.1302249

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Streptococcal IgA-binding proteins bind in the Calpha 2-Calpha 3 interdomain region and inhibit binding of IgA to human CD89.

Authors:  R J Pleass; T Areschoug; G Lindahl; J M Woof
Journal:  J Biol Chem       Date:  2000-11-28       Impact factor: 5.157

Review 2.  IgA nephropathy.

Authors:  Robert J Wyatt; Bruce A Julian
Journal:  N Engl J Med       Date:  2013-06-20       Impact factor: 91.245

3.  Th1/Th2 predominance and proinflammatory cytokines determine the clinicopathological severity of IgA nephropathy.

Authors:  C S Lim; S Zheng; Y S Kim; C Ahn; J S Han; S Kim; J S Lee; D W Chae; J R Koo; R W Chun; J W Noh
Journal:  Nephrol Dial Transplant       Date:  2001-02       Impact factor: 5.992

Review 4.  Pathogenesis of immunoglobulin A nephropathy: recent insight from genetic studies.

Authors:  Krzysztof Kiryluk; Jan Novak; Ali G Gharavi
Journal:  Annu Rev Med       Date:  2012-10-16       Impact factor: 13.739

5.  Heterogeneity of O-glycosylation in the hinge region of human IgA1.

Authors:  J Novak; M Tomana; M Kilian; L Coward; R Kulhavy; S Barnes; J Mestecky
Journal:  Mol Immunol       Date:  2000-12       Impact factor: 4.407

6.  Isolated hypervariable regions derived from streptococcal M proteins specifically bind human C4b-binding protein: implications for antigenic variation.

Authors:  E Morfeldt; K Berggård; J Persson; T Drakenberg; E Johnsson; E Lindahl; S Linse; G Lindahl
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

7.  Streptococcal beta protein has separate binding sites for human factor H and IgA-Fc.

Authors:  Thomas Areschoug; Margaretha Stålhammar-Carlemalm; Ingrid Karlsson; Gunnar Lindahl
Journal:  J Biol Chem       Date:  2002-01-25       Impact factor: 5.157

8.  Expression of Fc alpha/mu receptor by human mesangial cells: a candidate receptor for immune complex deposition in IgA nephropathy.

Authors:  Kenneth J McDonald; Angus J M Cameron; Janet M Allen; Alan G Jardine
Journal:  Biochem Biophys Res Commun       Date:  2002-01-11       Impact factor: 3.575

9.  Intraglomerular synthesis of complement C3 and its activation products in IgA nephropathy.

Authors:  K Abe; M Miyazaki; T Koji; A Furusu; K Shioshita; S Tsukasaki; Y Ozono; T Harada; H Sakai; S Kohno
Journal:  Nephron       Date:  2001-03       Impact factor: 2.847

Review 10.  IgA nephropathy: molecular mechanisms of the disease.

Authors:  Jiri Mestecky; Milan Raska; Bruce A Julian; Ali G Gharavi; Matthew B Renfrow; Zina Moldoveanu; Lea Novak; Karel Matousovic; Jan Novak
Journal:  Annu Rev Pathol       Date:  2012-10-18       Impact factor: 23.472

View more
  19 in total

1.  C4d deposits in IgA nephropathy: where does complement activation come from?

Authors:  Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2017-02-14       Impact factor: 3.714

Review 2.  Biomarkers and targeted new therapies for IgA nephropathy.

Authors:  Rosanna Coppo
Journal:  Pediatr Nephrol       Date:  2016-06-20       Impact factor: 3.714

3.  Intrinsic renal cells induce lymphocytosis of Th22 cells from IgA nephropathy patients through B7-CTLA-4 and CCL-CCR pathways.

Authors:  Lu Gan; Qiaoling Zhou; Xiaozhao Li; Chen Chen; Ting Meng; Jiaxi Pu; Mengyuan Zhu; Chenggen Xiao
Journal:  Mol Cell Biochem       Date:  2017-09-05       Impact factor: 3.396

Review 4.  Current Understanding of the Role of Complement in IgA Nephropathy.

Authors:  Nicolas Maillard; Robert J Wyatt; Bruce A Julian; Krzysztof Kiryluk; Ali Gharavi; Veronique Fremeaux-Bacchi; Jan Novak
Journal:  J Am Soc Nephrol       Date:  2015-02-18       Impact factor: 10.121

Review 5.  Renal diseases and the role of complement: Linking complement to immune effector pathways and therapeutics.

Authors:  Tilo Freiwald; Behdad Afzali
Journal:  Adv Immunol       Date:  2021-11-19       Impact factor: 3.543

6.  Collectin11 and Complement Activation in IgA Nephropathy.

Authors:  Min Wei; Wei-Yi Guo; Bo-Yang Xu; Su-Fang Shi; Li-Jun Liu; Xu-Jie Zhou; Ji-Cheng Lv; Li Zhu; Hong Zhang
Journal:  Clin J Am Soc Nephrol       Date:  2021-10-06       Impact factor: 8.237

7.  Interleukin-6 Downregulates the Expression of Vascular Endothelial-Cadherin and Increases Permeability in Renal Glomerular Endothelial Cells via the Trans-Signaling Pathway.

Authors:  Yong-Chang Yang; Hui Fu; Bo Zhang; Yu-Bin Wu
Journal:  Inflammation       Date:  2022-07-23       Impact factor: 4.657

Review 8.  Markers for the progression of IgA nephropathy.

Authors:  Dita Maixnerova; Colin Reily; Qi Bian; Michaela Neprasova; Jan Novak; Vladimir Tesar
Journal:  J Nephrol       Date:  2016-05-03       Impact factor: 3.902

9.  The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study.

Authors:  S K Grewal; J Wan; M R Denburg; D B Shin; J Takeshita; J M Gelfand
Journal:  Br J Dermatol       Date:  2017-03-05       Impact factor: 9.302

Review 10.  New therapeutic perspectives for IgA nephropathy in children.

Authors:  Alexandra Cambier; Patrick J Gleeson; Héloise Flament; Marie-Bénédicte Le Stang; Renato C Monteiro
Journal:  Pediatr Nephrol       Date:  2020-02-10       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.